FDA’s emergency use authorization process for monkeypox tests is more streamlined than it was for COVID-19 test EUAs in the early days of the coronavirus pandemic, experts say, but at the same time the agency has lagged behind on developing and disseminating guidance about the EUA process to monkeypox test developers. One source says the White House and federal agencies, including FDA, should work to develop a national testing strategy that allows the government to be more proactive in responding...